Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

Defy SDS, Defeat SCN, Increase Yield Opportunity with ILeVO

Bayer
Posted on: 28 Feb 18

RESEARCH TRIANGLE PARK, N.C., Feb. 27, 2018 /PRNewswire/ -- Yield results for 2017 are in and growers who want to add nearly 4-plus bu/A to their soybean yield can again turn to a proven, convenient solution: seven years of independent testing with universities and third-parties across U.S. soybean-growing states show ILeVO® seed treatment increases yield by 4.6 bu/A on average.

What this data tells us is ILeVO seed treatment protects seeds from the moment they are planted, so growers can plant earlier in the season with less risk of Sudden Death Syndrome (SDS) and Soybean Cyst Nematode (SCN) damage.

More than 355 SDS trials between 2011-2017 showed an average yield increase of 4.6 bu/A when seed was protected with ILeVO over seed treated with only a fungicide/insecticide base treatment. Yield increases were higher in fields with heavier levels of disease pressure and a history of SDS. In fields where SDS pressure was minimal, ILeVO still provided an average yield increase of more than 2 bu/A. Across the seven years, trial results indicate an 84 percent positive response rate across varying levels of pressure from SDS and SCN.

"These trial results show ILeVO provides consistent performance year-to-year across different environmental conditions," said Nick Tinsley, Bayer SeedGrowth technical service representative. "Even when we have years with lighter SDS pressure, the yield benefit from nematode protection is still present."

"Growers who adopt ILeVO increase their opportunity for yield when faced with different levels of pressure from nematodes and SDS, which raises their profit potential," added Melissa Chu, Bayer SeedGrowth product manager. 

Dr. Martin Chilvers, plant pathologist at Michigan State University, conducted test plot trials in 2017. In addition to a yield advantage, he also saw a suppression of SCN reproduction. 

"We ran around 30 SCN and SDS test plot trials and saw a 5 bu/A yield benefit with ILeVO over a base treatment," Chilvers said. "In fields where SDS was lighter, we still saw about a 2 bu/A yield advantage."

More information on how to use ILeVO as a proactive risk-management tool to combat SDS and SCN and increase your earning potential, is available from your Bayer representative, your local retailer and online at https://www.cropscience.bayer.us/products/seedgrowth/ilevo.

Bayer is committed to bringing new technology and solutions for agriculture and non-agricultural uses. For questions concerning the availability and use of products, contact a local Bayer representative, or visit Crop Science, a division of Bayer, online at www.cropscience.bayer.us.

Visit the Bayer Connect - Social Hub for social media, recent news, blog posts, videos and more from Crop Science, a division of Bayer.

About Bayer 
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 99,600 people and had sales of EUR 34.9 billion. Capital expenditures amounted to EUR 2.2 billion, R&D expenses to EUR 4.4 billion. For more information, go to www.bayer.com. 

Contact: 
Bayer Media Hotline, 1-862-404-5118, or

Linda Arnold Whaley 
Crop Science, a division of Bayer  
Tel: (919) 549-2836  
Email: Linda.arnoldwhaley@bayer.com

Bailey Harmon 
Rhea + Kaiser 
Tel: (630) 955-2418 
Email: Bharmon@rkconnect.com         

Find more information at www.cropscience.bayer.us. 

Forward-Looking Statements  
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

© 2018 Bayer CropScience LP, 2 T.W. Alexander Drive, Research Triangle Park, NC 27709. Always read and follow label instructions. Bayer, the Bayer Cross and ILeVO are registered trademarks of Bayer. For additional product information, call toll-free 1-866-99-BAYER (1-866-992-2937) or visit our website at www.cropscience.bayer.us.

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 28/02/2018

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.